SG11202111402PA - Anti-cancer nuclear hormone receptor-targeting compounds - Google Patents

Anti-cancer nuclear hormone receptor-targeting compounds

Info

Publication number
SG11202111402PA
SG11202111402PA SG11202111402PA SG11202111402PA SG11202111402PA SG 11202111402P A SG11202111402P A SG 11202111402PA SG 11202111402P A SG11202111402P A SG 11202111402PA SG 11202111402P A SG11202111402P A SG 11202111402PA SG 11202111402P A SG11202111402P A SG 11202111402PA
Authority
SG
Singapore
Prior art keywords
hormone receptor
nuclear hormone
targeting compounds
cancer nuclear
cancer
Prior art date
Application number
SG11202111402PA
Inventor
David Hung
Son Minh Pham
Sarvajit Chakravarty
Jiyun Chen
Jayakanth Kankanala
Jeremy D Pettigrew
Anup Barde
Anjan Kumar Nayak
Original Assignee
Nuvation Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvation Bio Inc filed Critical Nuvation Bio Inc
Publication of SG11202111402PA publication Critical patent/SG11202111402PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202111402PA 2019-05-14 2020-05-13 Anti-cancer nuclear hormone receptor-targeting compounds SG11202111402PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962847854P 2019-05-14 2019-05-14
US201962935069P 2019-11-13 2019-11-13
US201962938218P 2019-11-20 2019-11-20
PCT/US2020/032672 WO2020232119A1 (en) 2019-05-14 2020-05-13 Anti-cancer nuclear hormone receptor-targeting compounds

Publications (1)

Publication Number Publication Date
SG11202111402PA true SG11202111402PA (en) 2021-11-29

Family

ID=73230939

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111402PA SG11202111402PA (en) 2019-05-14 2020-05-13 Anti-cancer nuclear hormone receptor-targeting compounds

Country Status (13)

Country Link
US (1) US11826430B2 (en)
EP (1) EP3969050A4 (en)
JP (1) JP2022532342A (en)
KR (1) KR20220008869A (en)
CN (1) CN113811333B (en)
AU (1) AU2020274113A1 (en)
BR (1) BR112021022008A2 (en)
CA (1) CA3138197A1 (en)
CL (1) CL2021002986A1 (en)
IL (1) IL287911A (en)
MX (1) MX2021013774A (en)
SG (1) SG11202111402PA (en)
WO (1) WO2020232119A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11253603B2 (en) 2018-09-17 2022-02-22 The Children's Hospital Of Philadelphia Polymer-based macromolecular prodrugs
US20220218722A1 (en) * 2019-04-27 2022-07-14 Health Research, Inc. Coumarin-modified androgens for the treatment of prostate cancer
AU2020274113A1 (en) 2019-05-14 2021-11-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2021097046A1 (en) * 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114516877B (en) * 2020-11-20 2023-10-27 烟台弘邦医药科技有限公司 Preparation method of rebamipa intermediate
CN113024513A (en) * 2021-03-22 2021-06-25 中国药科大学 Novel androgen receptor degradation agent, preparation method and medical application
CA3214408A1 (en) 2021-03-23 2022-09-29 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
AU2022269568A1 (en) 2021-05-03 2023-11-16 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113788827B (en) * 2021-10-18 2023-04-25 中国药科大学 Phthalazinone compound, preparation method and medical application thereof

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3907290A1 (en) 1989-03-07 1990-09-13 Gerhard Prof Dr Eisenbrand STEROID HORMONE RECEPTOR AFFINES ANTITUARY ACTIVE SUBSTANCES
AU696788B2 (en) 1994-06-27 1998-09-17 Neutron Therapies Inc. Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors
WO1996005308A1 (en) 1994-08-12 1996-02-22 Myriad Genetics, Inc. Method for diagnosing a predisposition for breast and ovarian cancer
ATE201445T1 (en) 1994-08-12 2001-06-15 Myriad Genetics Inc MUTATIONS OF THE OVARIAL AND BREAST CANCER SENSITIVITY GENE LINKED TO 17Q
ATE307899T1 (en) 1994-11-01 2005-11-15 Ariad Gene Therapeutics Inc NEW METHOD FOR FINDING AND EVALUating BIOLOGICALLY ACTIVE MOLECULES
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
JP2003508402A (en) 1999-08-27 2003-03-04 リガンド・ファーマシューティカルズ・インコーポレイテッド Androgen receptor modulator compounds and methods
KR100731566B1 (en) 1999-10-14 2007-06-22 가켄 세야쿠 가부시키가이샤 Tetrahydroquinoline derivatives
AU2001255381A1 (en) 2000-04-12 2001-10-30 Trustees Of Boston University Selective nuclear receptor-targeted systems for delivery of cytotoxins to cancercells for targeted photodynamic therapy
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
WO2002022585A1 (en) 2000-09-14 2002-03-21 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline compounds
CA2463311A1 (en) 2001-10-19 2003-05-01 Paul J. Coleman Androgen receptor modulators and methods of use thereof
IL148825A0 (en) 2002-03-21 2002-09-12 Yeda Res & Dev Derivatives of isoflavones
ITRM20020305A1 (en) 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti CAMPTOTECINE WITH MODIFIED LATTON RING.
AU2003244313A1 (en) 2002-06-19 2004-01-06 Kaken Pharmaceutical Co., Ltd. Androgen receptor agonist
AU2003252333A1 (en) 2002-08-01 2004-02-23 Kaken Pharmaceutical Co., Ltd. Novel tetrahydroquinoline derivatives
US7622592B2 (en) 2002-11-01 2009-11-24 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
KR101146806B1 (en) 2003-03-12 2012-05-22 메이브릿지 리미티드 Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
AU2004232314B2 (en) 2003-04-22 2007-11-22 Ipsen Pharma S.A.S. Peptide vectors
WO2005000795A2 (en) 2003-06-10 2005-01-06 Smithkline Beecham Corporation Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators
JP2007505164A (en) 2003-06-10 2007-03-08 スミスクライン ビーチャム コーポレーション 1-aminonaphthalenes as modulators of androgens, glucocorticoids, mineralocorticoids and progesterone receptors
DK1656360T3 (en) 2003-06-13 2007-12-27 Janssen Pharmaceutica Nv Thiazoline derivatives as selective androgen receptor modulators
US20070275911A1 (en) 2003-09-05 2007-11-29 Koch Tad H Targeted Drug-Formaldehyde Conjugates and Methods of Making and Using the Same
US7220730B2 (en) 2003-09-25 2007-05-22 Board Of Regents Of The University Of Nebraska Cancer specific radiolabeled conjugates regulated by the cell cycle for the treatment and diagnosis of cancer
ATE521341T1 (en) * 2003-12-01 2011-09-15 Kudos Pharm Ltd DNA DAMAGE REPAIR INHIBITORS FOR TREATING CANCER
EP1725522B1 (en) 2004-03-03 2014-09-10 GlaxoSmithKline LLC Aniline derivatives as selective androgen receptor modulators
EP1773754A2 (en) 2004-03-10 2007-04-18 Massachussets Institute of Technology Methods and compositions for treating cancer
WO2005111042A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
US7282507B2 (en) 2004-05-03 2007-10-16 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (SARMS)
US20080045504A1 (en) 2004-05-11 2008-02-21 Pfizer Products Inc. Benzonitrile Derivatives to Treat Musculoskeletal Frailty
CA2566942A1 (en) 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
WO2005118612A1 (en) 2004-06-04 2005-12-15 Sonus Pharmaceuticals, Inc. Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006031715A2 (en) 2004-09-10 2006-03-23 Janssen Pharmaceutica N.V. Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms)
US7834063B2 (en) 2004-10-13 2010-11-16 Glaxosmithkline Llc Benzonitryl and nitrobenzyl derivatives that modulate androgen receptors
EP1807076A4 (en) 2004-10-29 2010-06-02 Merck Sharp & Dohme N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
CA2587678C (en) 2004-11-16 2013-05-21 Janssen Pharmaceutica N.V. Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms)
AU2006205066B2 (en) 2005-01-10 2012-05-17 Acadia Pharmaceuticals Inc. Aminophenyl derivatives as selective androgen receptor modulators
ES2314922T3 (en) 2005-05-13 2009-03-16 Eli Lilly And Company N-ARILPIRROLIDINAS REPLACED AS SELECTIVE MODULATORS OF THE ANDROGEN RECEIVER.
WO2006133216A2 (en) 2005-06-06 2006-12-14 Smithkline Beecham Corporation 4-substituted arylamine derivatives and their use in pharmaceutical compositions
BRPI0611705A2 (en) 2005-06-24 2016-11-16 Lilly Co Eli compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and use of compound
US20070122843A1 (en) 2005-09-23 2007-05-31 Fazlul Sarkar Isoflavonoid analogs and their metal complexes as anti-cancer agents
GB0701273D0 (en) 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
WO2009005839A2 (en) 2007-07-03 2009-01-08 The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Service Compounds and methods of use
US20090062268A1 (en) 2007-08-27 2009-03-05 Lead Therapeutics, Inc. Novel inhibitors of poly(adp-ribose)polymerase (parp)
GB0718045D0 (en) 2007-09-14 2007-10-24 Peptcell Ltd Pharmaceutical compound
US8184109B2 (en) * 2007-10-24 2012-05-22 Wacom Co., Ltd. Coordinate input device, position indicator and variable capacitor
EP2217227B1 (en) 2007-11-12 2013-08-21 BiPar Sciences, Inc. Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
US20090257999A1 (en) * 2007-12-31 2009-10-15 Inotek Pharmaceuticals Corporation Method of preventing contrast-induced nephropathy
UY31603A1 (en) * 2008-01-23 2009-08-31 DERIVATIVES OF FTALAZINONA
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009114459A2 (en) * 2008-03-10 2009-09-17 The Trustees Of The University Of Pennsylvania Anti-neoplastic combination therapeutic regimen involving co-disruption of parp pathway and mre11/rad50/nbs1 complex and compositons useful therein
WO2009126606A2 (en) * 2008-04-10 2009-10-15 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Regression of established atherosclerotic plaques, and treating sudden-onset asthma attacks, using parp inhibitors
US20110104074A1 (en) 2008-06-18 2011-05-05 University Of Louisville Research Foundation, Inc. Methods for targeted cancer treatment and detection
BRPI0917119B1 (en) 2008-08-06 2021-07-13 Medivation Technologies, Inc. COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF THE SAME AND ITS MANUFACTURING PROCESS
TW201028410A (en) 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
WO2010085747A1 (en) 2009-01-23 2010-07-29 Northeastern University Steroidal anti-hormone hybrids
BRPI0901157A2 (en) 2009-03-27 2010-11-16 Univ Fed Pernambuco antineoplastic-testosterone molecular complex
US8785501B2 (en) 2009-10-13 2014-07-22 Duquesne University Of The Holy Spirit Anti-cancer tamoxifen-melatonin hybrid ligand
JP5982361B2 (en) 2010-04-16 2016-08-31 モメンタ ファーマシューティカルズ インコーポレイテッド Tissue targeting method
SA111320519B1 (en) 2010-06-11 2014-07-02 Astrazeneca Ab Pyrimidinyl Compounds for Use as ATR Inhibitors
JP2013532683A (en) 2010-07-27 2013-08-19 カディラ ヘルスケア リミティド Substituted 4- (4-fluoro-3- (piperazin-1-carbonyl) benzyl) phthalazin-1 (2H) -one derivatives as poly (ADP ribose) polymerase-1 inhibitors
CN101967172A (en) 2010-09-15 2011-02-09 东北林业大学 Novel derivates of camptothecin 10-position coupled bile acid
CN101967173A (en) 2010-09-15 2011-02-09 东北林业大学 Novel camptothecin derivative coupled with cholic acid at position 10
CN101948500A (en) 2010-09-15 2011-01-19 东北林业大学 New derivative of camptothecin 20-site coupled bile acid
WO2012050868A1 (en) 2010-09-28 2012-04-19 Georgia Tech Research Corporation Histone deacetylase (hdac) inhibitors targeting prostate tumors and methods of making and using thereof
WO2012074840A2 (en) 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
US20140088178A1 (en) * 2011-03-14 2014-03-27 The University Of British Columbia Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer
WO2012134446A1 (en) 2011-03-29 2012-10-04 SUTTER WEST BAY HOSPITALS doing business as CALIFORNIA PACIFIC MEDICAL CENTER Epiandrosterone and/or androsterone derivatives and method of use thereof
WO2013028495A1 (en) 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
JP5934986B2 (en) 2011-09-07 2016-06-15 公益財団法人ヒューマンサイエンス振興財団 Apoptosis-inhibiting protein ligand-estrogen receptor ligand hybrid compound, estrogen receptor degradation inducer using the same, and preventive and therapeutic agent for breast cancer, cervical cancer or ovarian cancer
CN102492009A (en) 2011-12-15 2012-06-13 东北林业大学 Camptothecin 20- position cholic acid derivative and preparation method thereof
CN102532237A (en) 2011-12-15 2012-07-04 东北林业大学 Camptothecin tenth-position cholic acid coupling compound and preparation method thereof
CN102492010A (en) 2011-12-15 2012-06-13 东北林业大学 Derivatives of camptothecin 20-site bile acid and preparation method thereof
CN102516347A (en) 2011-12-15 2012-06-27 东北林业大学 Camptothecin 20-site cholic acid derivative and preparation method thereof
RU2666530C2 (en) 2012-01-12 2018-09-11 Йейл Юниверсити Compounds and methods for enhanced degradation of target proteins and other polypeptides by an e3 ubiquitin ligase
WO2013166110A1 (en) 2012-05-02 2013-11-07 Yale University Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
EP2861256B1 (en) 2012-06-15 2019-10-23 The Brigham and Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
US11873281B2 (en) 2012-07-12 2024-01-16 Hangzhou Dac Biotech Co., Ltd. Conjugates of cell binding molecules with cytotoxic agents
US9969683B2 (en) * 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) * 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
ES2701076T3 (en) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Hydrophilic linkers and their uses for the conjugation of drugs to molecules that bind to cells
GB201311910D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
EP3004090B1 (en) * 2013-05-28 2017-10-25 Astrazeneca AB Chemical compounds
US20160115192A1 (en) 2013-06-10 2016-04-28 Cedars-Sinai Medical Center Antioxidant, anti-inflammatory and anticancer derivatives of triptolide and nanospheres thereof
CN104292290A (en) 2013-07-16 2015-01-21 中国人民解放军军事医学科学院毒物药物研究所 Bile acid-drug conjugate with amino acid as connexon, and medical application thereof
EP3035938B1 (en) 2013-09-10 2020-08-19 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
WO2015095755A1 (en) 2013-12-19 2015-06-25 Seattle Genetics, Inc. Methylene carbamate linkers for use with targeted-drug conjugates
CN106456795A (en) 2014-03-03 2017-02-22 辛塔医药品有限公司 Targeted therapeutics
MA39483A (en) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp TARGET THERAPEUTIC AGENTS
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN105315294B (en) 2014-06-26 2018-05-01 王杭祥 7-Ethyl-10-hydroxycamptothecin prodrug and its preparation method and application
WO2016025480A1 (en) 2014-08-11 2016-02-18 The General Hospital Corporation Cyclooctenes for bioorthogonol reactions
SG11201703803WA (en) 2014-11-11 2017-06-29 Amunix Operating Inc Targeted xten conjugate compositions and methods of making same
US9980947B2 (en) 2014-12-18 2018-05-29 Genentech, Inc. Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
AU2016209349B2 (en) 2015-01-20 2020-05-07 Arvinas, Inc. Compounds and methods for the targeted degradation of the Androgen Receptor
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2016149668A1 (en) 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
TWI704137B (en) * 2015-05-29 2020-09-11 日商衛材R&D企管股份有限公司 Tetrasubstituted alkene compounds and their use
CN108136044B (en) 2015-06-04 2021-08-10 阿尔维纳斯运营股份有限公司 Imide-based proteolytic modulators and related methods of use
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
EP3307749A4 (en) 2015-06-15 2019-06-19 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers for conjugation
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
CN113698335A (en) 2015-07-04 2021-11-26 杭州多禧生物科技有限公司 Specific conjugation of cell binding molecules
AU2016291578C1 (en) 2015-07-10 2021-07-15 Arvinas Operations, Inc. MDM2-based modulators of proteolysis and associated methods of use
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US20170037004A1 (en) 2015-07-13 2017-02-09 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
WO2015155753A2 (en) 2015-08-10 2015-10-15 Suzhou M-Conj Biotech Co., Ltd Novel linkers and their uses in specific conjugation of drugs to a biological molecule
EP3912680A1 (en) 2015-10-01 2021-11-24 Olema Pharmaceuticals, Inc. Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
US9963433B2 (en) 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
AU2016202632B2 (en) 2016-02-04 2021-09-09 Hangzhou Dac Biotech Co, Ltd Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
JP2019094260A (en) 2016-03-28 2019-06-20 国立大学法人東北大学 Nanoparticulate formulations for cancer disease treatment
CN107286166B (en) 2016-04-11 2020-03-31 上海勋和医药科技有限公司 Substituted 1,3,4, 5-tetrahydro-6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one derivatives
GB201608885D0 (en) 2016-05-20 2016-07-06 Univ Birmingham Treatment
EP3468500A4 (en) 2016-06-09 2020-03-04 Blinkbio Inc. Silanol based therapeutic payloads
WO2018019793A1 (en) * 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
US10054602B2 (en) 2016-08-19 2018-08-21 Christ University Conjugate of estradiol and applications thereof
JP6997172B2 (en) * 2016-08-24 2022-01-17 サイノファーム タイワン，リミティド How to make olaparib
PL3660004T3 (en) 2016-10-11 2023-10-02 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP3554526B1 (en) 2016-12-14 2024-05-08 Purdue Research Foundation Luteinizing hormone-releasing hormone receptor (lhrh-r) conjugates and uses thereof
IL294423B2 (en) 2016-12-23 2024-01-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
EP3585433A4 (en) 2017-02-23 2020-12-30 Rakuten Medical, Inc. Therapeutic compositions and related methods for photoimmunotherapy
SG11201908721TA (en) 2017-04-06 2019-10-30 Hangzhou Dac Biotech Co Ltd Conjugation of a cytotoxic drug with bis-linkage
JP7320455B2 (en) 2017-06-21 2023-08-03 グリコス・フィンランド・オーワイ Hydrophilic linkers and their conjugates
CN107266520A (en) 2017-06-28 2017-10-20 湖南华腾制药有限公司 A kind of camptothecine and birch acid conjugate and preparation method thereof
BR112020001825A2 (en) 2017-07-28 2020-07-21 Arvinas Operations, Inc. compounds and methods for targeted androgen receptor degradation
CN108014347B (en) 2017-11-23 2021-05-04 金志明 Glutamic acid polypeptide-estrogen/antiestrogen conjugate, synthetic method, composition and kit
US10519152B2 (en) * 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
EP3773727A4 (en) 2018-04-09 2022-05-04 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
AU2019251223A1 (en) 2018-04-13 2020-11-26 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN112566666A (en) * 2018-05-14 2021-03-26 努瓦申生物公司 Compounds targeting anti-cancer nuclear hormone receptors
WO2019241231A1 (en) 2018-06-11 2019-12-19 Abhishek Sharma Antiestrogen compounds
WO2020023851A1 (en) 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020113088A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
US11478493B2 (en) 2019-03-08 2022-10-25 University Of South Carolina Fabrication and application of a hetero-targeted nano-cocktail with traceless linkers
US20200297725A1 (en) 2019-03-22 2020-09-24 Yale University Allosteric bcr-abl proteolysis targeting chimeric compounds
AU2020274113A1 (en) 2019-05-14 2021-11-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2020257998A1 (en) 2019-06-24 2020-12-30 Hangzhou Dac Biotech Co., Ltd A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers
AU2020318599B2 (en) 2019-07-19 2023-09-07 Astrazeneca Ab PARP1 inhibitors
CA3154678A1 (en) 2019-09-18 2021-03-25 The Regents Of The University Of California Biaminoquinolines and nanoformulations for cancer treatment
WO2021097046A1 (en) 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP2023530128A (en) 2020-06-19 2023-07-13 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． Conjugates of cell binding molecules and camptothecin analogues
WO2022035818A2 (en) 2020-08-11 2022-02-17 Peptinovo Biopharma, Inc. Peptides and formulations for cancer treatment
CN116249525A (en) 2020-08-21 2023-06-09 芝加哥大学 Nanoparticles containing multiple cleavable prodrugs for cancer therapy
KR20230111615A (en) 2020-10-21 2023-07-25 아비나스 오퍼레이션스, 인코포레이티드 Compounds and methods for targeted degradation of androgen receptor proteins
EP4240733A1 (en) 2020-11-06 2023-09-13 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
CA3214408A1 (en) 2021-03-23 2022-09-29 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
AU2022269568A1 (en) 2021-05-03 2023-11-16 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds

Also Published As

Publication number Publication date
EP3969050A4 (en) 2023-11-01
CA3138197A1 (en) 2020-11-19
KR20220008869A (en) 2022-01-21
CN113811333A (en) 2021-12-17
CN113811333B (en) 2024-03-12
WO2020232119A1 (en) 2020-11-19
AU2020274113A1 (en) 2021-11-11
US20200360523A1 (en) 2020-11-19
US11826430B2 (en) 2023-11-28
JP2022532342A (en) 2022-07-14
IL287911A (en) 2022-01-01
CL2021002986A1 (en) 2022-09-23
MX2021013774A (en) 2021-12-10
EP3969050A1 (en) 2022-03-23
BR112021022008A2 (en) 2022-05-17

Similar Documents

Publication Publication Date Title
SG11202011135WA (en) Anti-cancer nuclear hormone receptor-targeting compounds
IL287911A (en) Anti-cancer nuclear hormone receptor-targeting compounds
IL292753A (en) Compounds
IL289463A (en) Gipr-agonist compounds
IL308104A (en) Anti-cancer nuclear hormone receptor-targeting compounds
IL306010A (en) Anti-cancer nuclear hormone receptor-targeting compounds
GB201905721D0 (en) Compounds
GB201916915D0 (en) Compounds
GB201910305D0 (en) Compounds
GB201908536D0 (en) Compounds
GB201908171D0 (en) Compounds
SG11202111838SA (en) Glp-1 secretion-promoting composition
GB201910304D0 (en) Compounds
GB201908095D0 (en) Carboxy-MIDA-boronate compounds
DK3947966T3 (en) Fremgangsmåde til at detektere et læk i et hydraulisk pitchsystem
HUE057420T2 (en) Benzylhemiformal-containing biodiesel compounds
GB201919205D0 (en) Compounds
GB201918761D0 (en) Compounds
GB201918424D0 (en) Compounds
GB201917893D0 (en) Compounds
GB201917895D0 (en) Compounds
GB201916847D0 (en) Compounds
GB201916597D0 (en) Compounds
GB201916595D0 (en) Compounds
GB201916572D0 (en) Compounds